title: [Clinical and neurophysiological objectification and evaluation of treatment efficacy in children with perinatal hypoxic-ischemic injury of the CNS].
abstract: OBJECTIVE
  To objectify indications for treatment with pantogam in premature infants with perinatal hypoxic-ischemic injury of the CNS.
  
  
  METHODS
  We studied 71 children, with GA (gestation age) 24-36 weeks (32,9±2,9 weeks), with perinatal hypoxic-ischemic injury of the CNS, I-II grades, and hyperexitability syndrome. The main group (33 patients) received pantogam in dose 50 mg/kg/day at the adjusted age (AA) 36-40 weeks from the conception. The comparison group included 38 patients. EEG day sleep monitoring was performed before and at the end of treatment.
  
  
  RESULTS
  Shortening of sleep cycle was observed in 78,8% children of the main group and in 78,9% of the comparison group. Duration of transitional sleep over 1 min was 78,79% and 81,58%. At AA 44-46 weeks, the frequency of sleep disorders decreased to 45,45% (p=0,012) and 52,63% (p=0,05). Duration of transitional sleep over 1 min was 45,45% and 65,79%. Duration of the latent period of the 2nd stage of slow wave sleep was 6,4±2,57 and 12,5±7,18 min (p=0,0004).
  
  
  CONCLUSIONS
  The treatment reduced sleep disorders, changed the duration of transitional sleep stage and latent period of the 2nd stage of slow wave sleep.
authors.forename: O V
authors.initials: OV
authors.lastname: Grebennikova
authors.forename: A N
authors.initials: AN
authors.lastname: Zavadenko
authors.forename: S O
authors.initials: SO
authors.lastname: Rogatkin
authors.forename: M I
authors.initials: MI
authors.lastname: Medvedev
authors.forename: M G
authors.initials: MG
authors.lastname: Degtiareva
mesh_terms: D002648:Child; D002675:Child, Preschool; D004569:Electroencephalography; D005260:Female; D006801:Humans; D006948:Hyperkinesis / Q000188:drug therapy / Q000209:etiology; D020925:Hypoxia-Ischemia, Brain / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D007234:Infant, Premature; D008297:Male; D010205:Pantothenic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012894:Sleep Stages / Q000187:drug effects; D012893:Sleep Wake Disorders / Q000188:drug therapy* / Q000209:etiology; D016896:Treatment Outcome; D014202:Tremor / Q000188:drug therapy / Q000209:etiology; D005680:gamma-Aminobutyric Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: C016030:pantogab; D010205:Pantothenic Acid; D005680:gamma-Aminobutyric Acid